Q1/2025 3/31/2025 EPS -0.280 ZacksConsensus -0.280 ActVsEst 0.000 - In-Line
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOGlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Foresight Diagnostics Presents Independent Validation of its CLARITY Minimal Residual Disease (MRD) Assay in Multicenter Study of Frontline DLBCL at the 2025 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
ALLO
Earnings
- 5/13/25 - In-Line
ALLO
Sec Filings
- 6/23/25 - Form 4
- 6/23/25 - Form 4
- 6/23/25 - Form 4
- ALLO's page on the SEC website